BETABeta Drugs Ltd.

₹1738+0.40%

Market Cap

₹1,747.37 Cr

Stock P/E

41.19

ROCE

32.74%

ROE

26.03%

Book Value

₹195.25

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Public

Others

From Last Concall

POSITIVES

•
No positives identified due to unavailable transcript.
•
Transcript content missing prevents validation of operational metrics.

NEGATIVES

•
No transcript to extract negatives from Q&A or strategic updates.
•
Cannot verify financials or guidance from the current file.

Peers Summary

Sector Leader

Beta Drugs Ltd. shows impressive growth metrics and profitability compared to its peers, making it a strong contender in the Pharmaceuticals & Drugs sector. Its low debt levels and high ROE further enhance its attractiveness, positioning it as a potential sector leader alongside a few other outperformers. Conversely, companies like Divi's Laboratories Ltd. exhibit concerning financial metrics, indicating potential risks.

Key Points

• Beta Drugs Ltd. has the highest EPS growth and ROE among peers.
• Cipla Ltd. stands out as a best-value pick due to its low PE and strong profitability.
• Divi's Laboratories Ltd. is financially weak with negative growth and high valuation ratios.

Top Performers

Beta Drugs Ltd.

Highest EPS growth (42.02%) and ROE (26.03%) among peers.

Cipla Ltd.

Low PE (23.73) with solid profitability metrics, making it attractive.

Mankind Pharma Ltd.

Strong revenue growth (18.12% YoY) coupled with high ROE (23.15%).

Explore

Watchlists